Modus stays the course for $15.8m series A

Modus Therapeutics, a Sweden-based sickle cell disease therapy developer spun out from Karolinska Institute and Uppsala University, has secured SEK140m ($15.8m) in series A funding from investors including VC firm HealthCap.

The $15.8m includes HealthCap’s $6.8m investment and an additional $9m from conversion of existing notes from prior rounds.

Founded in 2011, Modus Therapeutics is developing a drug called sevuparin to help assuage sickle cell disease, a group of genetic abnormalities affecting the shape of red blood cells, consequently hindering…